Senseonics Holdings, Inc. has made its first commercial launch of the Eversense 365 implantable continuous glucose monitor in Sweden, marking the company’s entry into the European market. The 365‑day sensor eliminates the need for weekly sensor changes, offering patients a single implant that delivers accurate glucose readings for an entire year and broadening the company’s addressable patient base by more than 30 million across the region.
The Swedish rollout is the first phase of a planned expansion that will include Germany, Spain and Italy in the coming weeks. The launch follows Senseonics’ recent transition to a direct‑to‑consumer commercial model in the United States, a move designed to accelerate adoption of the one‑year CGM in markets where implantable technology has not yet been offered.
In the fourth quarter of 2025, Senseonics reported net revenue of $14.3 million, up 72% year‑over‑year, and a gross profit of $7.7 million, a jump from $4.0 million in the same quarter of 2024. Full‑year 2025 revenue reached $35.3 million, up 57% YoY, while the company guided 2026 global net revenue to $58–$62 million, representing 65–76% growth. Gross margins are expected to average 50% in 2026, but the company continues to post net losses—$20.8 million in Q4 2025 and $69.1 million for the full year—largely due to increased SG&A expenses associated with bringing commercialization in‑house.
"This launch of Eversense 365 is a significant breakthrough for diabetes technology in Europe and for Senseonics as a business, as we successfully transition to an end‑to‑end commercial organization this year. Building on demonstrable commercial momentum in the U.S., European expansion is a key part of our Eversense 365 growth strategy, increasing our total addressable market by over 30 million patients," said CEO Tim Goodnow. "The excitement for Eversense 365 was palpable at ATTD and we’re thrilled to now offer this life‑changing technology to the first patients in Europe. Real‑world evidence showcases Eversense 365’s unique benefits—delivering one year of exceptionally accurate monitoring with minimal interruptions—enabling patients to focus on managing their diabetes and not their CGM," added Chief Commercial Officer Brian Hansen. CFO Frederick Sullivan noted, "In the fourth quarter of 2025, net revenue grew 72% to $14.3 million compared to $8.3 million in the prior year period."
The one‑year implantable sensor differentiates Senseonics from established wearable CGM providers such as Dexcom and Abbott, whose products typically require 10–15 day sensor changes. The Eversense 365 platform also integrates with Sequel Med Tech’s twiist automated insulin delivery system, positioning the company at the forefront of hybrid‑closed loop solutions. Beyond the current launch, Senseonics is developing next‑generation technologies, including a self‑powered Gemini sensor and a Freedom system that would eliminate the need for an external transmitter.
The European launch expands Senseonics’ market reach and demonstrates the commercial viability of its implantable platform outside the United States. By capturing a new customer base and reinforcing its direct‑to‑consumer model, the company is poised to accelerate revenue growth, strengthen its competitive position, and lay the groundwork for further international expansion.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.